Cedra appoints Anthony Busa

pharmafile | May 14, 2010 | Appointment | Research and Development CRO, Cedra, appointment, research and development 

Phase I clinical trial specialist Cedra Corp division has appointed Anthony Busa as its new permanent chief executive, replacing acting chief executive Thomas Wardle.

Wardle also serves as Cedra’s chief operating officer and stepped into the chief executive role after company founder David Garcia stepped down earlier this year.

Busa has over 34 years of experience in management positions including senior level management, regional and national sales and product development within the pharmaceutical and medical device industries.

Advertisement

“Anthony is an experienced, high caliber professional. He has a thorough understanding of how this business and industry functions,” said Wardle. “He will be a great asset to our team in terms of growth and management.”

Busa previously held senior management positions at McClintic Busa Group, dgd Research, Esoterix, Medsites and Covance.

Related Content

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

The Gateway to Local Adoption Series

Latest content